Rethinking the laryngopharyngeal reflux treatment algorithm: Evaluating an alternate empiric dosing regimen and considering up-front, pH-impedance, and manometry testing to minimize cost in treating suspect laryngopharyngeal reflux disease.

Autor: Carroll TL; Department of Surgery, Division of Otolaryngology, Brigham and Women's Hospital, Boston, Massachusetts, U.S.A.; Department of Otolaryngology, Harvard Medical School, Boston, Massachusetts, U.S.A., Werner A; Tufts Medical School, Boston, Massachusetts, U.S.A., Nahikian K; Tufts Medical School, Boston, Massachusetts, U.S.A., Dezube A; Tufts Medical School, Boston, Massachusetts, U.S.A., Roth DF; Department of Otolaryngology, Tufts Medical Center, Boston, Massachusetts, U.S.A.
Jazyk: angličtina
Zdroj: The Laryngoscope [Laryngoscope] 2017 Oct; Vol. 127 Suppl 6, pp. S1-S13. Date of Electronic Publication: 2017 Aug 26.
DOI: 10.1002/lary.26806
Abstrakt: Objectives/hypothesis: Empiric proton pump inhibitor (PPI) trials for laryngopharyngeal reflux (LPR) are common. A majority of the patients respond to acid suppression. This work intends to evaluate once-daily, 40 mg omeprazole and once-nightly, 300 mg ranitidine (QD/QHS) dosing as an alternative regimen, and use this study's cohort to evaluate empiric regimens prescribed for LPR as compared to up-front testing with pH impedance multichannel intraluminal impedance (MII) with dual pH probes and high-resolution manometry (HRM) for potential cost minimization.
Study Design: Retrospective cohort review and cost minimization study.
Methods: A chart review identified patients diagnosed with LPR. All subjects were treated sequentially and outcomes recorded. Initial QD/QHS dosing increased after 3 months to BID if no improvement and ultimately prescribed MII and HRM if they failed BID dosing. Decision tree diagrams were constructed to determine costs of two empiric regimens and up-front MII and HRM.
Results: Ninety-seven subjects met the criteria. Responders and nonresponders to empiric therapy were identified. Seventy-two subjects (74%) responded. Forty-eight (67% of responders and 49% of all) improved with QD/QHS dosing. Forty-nine (51%) subjects escalated to BID dosing. Twenty-four subjects (33% of responders and 25% of all) improved on BID therapy. Twenty-five subjects (26%) did not respond to acid suppression. Average weighted cost was $1,897.00 per patient for up-front testing, $3,033.00 for initial BID, and $3,366.00 for initial QD/QHS.
Conclusions: An alternate QD/QHS regimen improved the majority who presented with presumed LPR. Cost estimates demonstrate that the QD/QHS regimen was more expensive than the initial BID high-dose PPI for 6 months. Overall per-patient cost appears less with up-front MII and HRM.
Level of Evidence: 4. Laryngoscope, 127:S1-S13, 2017.
(© 2017 The American Laryngological, Rhinological and Otological Society, Inc.)
Databáze: MEDLINE
Externí odkaz: